ADAGE: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Sponsor
Federation Francophone de Cancerologie Digestive (Other)
Overall Status
Recruiting
CT.gov ID
NCT02355379
Collaborator
(none)
774
140
4
127
5.5
0

Study Details

Study Description

Brief Summary

Colorectal cancer occurs mainly in elderly patients. Recent estimation showed that in France more than 50% of the patients diagnosed with a colorectal cancer are 70 years old or more. Adjuvant chemotherapy has demonstrated a benefit on disease-free survival and overall survival after a stage III colon cancer resection. Nevertheless adjuvant chemotherapy is poorly used in elderly patients. Prognostic improvement with chemotherapy based on 5FU is suggested by a post-hoc analysis of randomized prospective clinical trial. But elderly patients in this study were highly selected and patients older than 80 represented only 0.7% of the total population. Thus, there is still a concern about the benefit of adjuvant 5FU-based chemotherapy in very elderly unselected patients.

The recommended treatment for stage III adjuvant chemotherapy is a combination of fuoropyrimidine and oxaliplatin. Nevertheless oxaliplatin did not demonstrated survival advantage in elderly patients.

Altogether there are still two matters of debate:
  • First, is there a benefit of fluoropyrimidine-based adjuvant chemotherapy for unfit elderly patients?

  • Second, is there a benefit of oxaliplatin-based adjuvant chemotherapy for fit elderly patients? The aim of this randomized phase III study is to evaluate the benefit for disease-free survival of adjuvant chemotherapy in elderly patient and which chemotherapy.

The elderly patient population will be dichotomized into two groups according to physician's choice after a multidisciplinary evaluation involving a geriatrician, with two different randomization assignments. The patients with an expected life-expectancy below 4 years according Lee score are excluded of this study.

Some biological tumour abnormalities are more frequently observed in elderly (i.e. mismatch repair deficiency), therefore an evaluation of specific biological prognostic factors is needed in elderly population.

Condition or Disease Intervention/Treatment Phase
  • Drug: LV5FU2 or capectitabine
  • Drug: FOLFOX4 or XELOX
  • Other: Observation
  • Drug: LV5FU2 or capecitabine
Phase 3

Detailed Description

Colorectal cancer occurs mainly in elderly patients. Recent estimation showed that in France more than 50% of the patients diagnosed with a colorectal cancer are 70 years old or more. Adjuvant chemotherapy has demonstrated a benefit on disease-free survival and overall survival after a stage III colon cancer resection. Nevertheless adjuvant chemotherapy is poorly used in elderly patients. Prognostic improvement with chemotherapy based on 5FU is suggested by a post-hoc analysis of randomized prospective clinical trial. But elderly patients in this study were highly selected and patients older than 80 represented only 0.7% of the total population. Thus, there is still a concern about the benefit of adjuvant 5FU-based chemotherapy in very elderly unselected patients.

The recommended treatment for stage III adjuvant chemotherapy is a combination of fuoropyrimidine and oxaliplatin. Nevertheless oxaliplatin did not demonstrated survival advantage in elderly patients.

Altogether there are still two matters of debate:
  • First, is there a benefit of fluoropyrimidine-based adjuvant chemotherapy for unfit elderly patients?

  • Second, is there a benefit of oxaliplatin-based adjuvant chemotherapy for fit elderly patients? The aim of this randomized phase III study is to evaluate the benefit for disease-free survival of adjuvant chemotherapy in elderly patient and which chemotherapy.

The elderly patient population will be dichotomized into two groups according to physician's choice after a multidisciplinary evaluation involving a geriatrician, with two different randomization assignments. The patients with an expected life-expectancy below 4 years according Lee score are excluded of this study.

Some biological tumour abnormalities are more frequently observed in elderly (i.e. mismatch repair deficiency), therefore an evaluation of specific biological prognostic factors is needed in elderly population.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
774 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi
Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Aug 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: GROUP1 -ARM A

LV5FU2 or capecitabine

Drug: LV5FU2 or capectitabine

Experimental: GROUP1-ARMB

FOLFOX4 or XELOX

Drug: FOLFOX4 or XELOX

Experimental: GROUP2- ARM C

Observation

Other: Observation

Experimental: GROUP2-ARM D

LV5FU2 or capecitabine

Drug: LV5FU2 or capecitabine

Outcome Measures

Primary Outcome Measures

  1. The 3-year disease-free survival [3 years after last patient in]

Secondary Outcome Measures

  1. Overal survival [5 years after last patient in]

  2. Observed toxicities, graded according to NCI-CTC v4 [3 years after last patient in]

Eligibility Criteria

Criteria

Ages Eligible for Study:
75 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 70 years

  • Patient considered able to receive chemotherapy

  • Lee score detailed faxed to CRGA

  • Stage III colon adenocarcinoma

  • R0 resection of the primary tumor

  • Start of the potential adjuvant chemotherapy within 12 weeks after surgery

  • No prior chemotherapy for colon cancer

  • Geriatric Self-administered questionnaire completed faxed to CRGA

  • Geriatric Questionnaire completed by the team faxed to CRGA

  • Effective contraception for men patients throughout treatment and for at least 6 months after discontinuation of oxaliplatin

  • Consent signed

Exclusion Criteria:
  • Other progressive disease (cancer uncontrolled for less than 2 years)

  • Rectal Cancer (located less than 15 cm from the anal verge endoscopy or sub-peritoneal)

  • ANC <2000 / mm3 for group 1 and ANC <1500 / mm3 for group 2 and platelets <100,000 / mm3 or hemoglobin <9 g / dL

  • Neuropathy for patients in group 1

  • Known deficit of dihydropyrimidine dehydrogenase (DPD)

  • Patients with severe hepatic insufficiency

  • Any contrindication to the drugs used in the study

  • Inability to submit to medical follow-up for geographical, social or psychological reasons.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Fort de France Fort De France Guadeloupe France 97261
2 CH d'Abbeville Abbeville CEDEX France 80142
3 CROMG Agen France
4 Centre hospitalier du Pays d'Aix Aix-en-Provence France 13616
5 Centre hospitalier d'Albi Albi France 81000
6 Clinique Claude Bernard Albi France 81030
7 Clinique Claude Bernard Albi France
8 Centre Oncogard Alès France 30103
9 Hôpital Sud Amiens CEDEX 1 France 80054
10 ICO Site Paul Papin Angers CEDEX 2 France 49055
11 CHU d'Angers Angers CEDEX 9 France 49933
12 HOP Privé Annemasse France
13 CH Victor Dupouy Argenteuil France 95107
14 Hôpital Les Bonnettes Arras CEDEX France 62012
15 Hôpital Privé Bonnettes Arras France
16 Centre Hospitalier Ardèche Méridionale Aubenas CEDEX France 07205
17 CH D'Auxerre Auxerre France 89000
18 Institut Sainte Catherine Avignon CEDEX France 84918
19 Hôpital Henri Duffaut Avignon France 84902
20 Hôpital de Bayeux Bayeux CEDEX France 14401
21 CH Côte Basque Bayonne CEDEX France 64109
22 Centre d'Oncologie et de Radiothérapie du Pays-Basque Bayonne France 64100
23 CH de Beauvais Beauvais France 60021
24 CH de Blois Blois France 41000
25 CHU Avicenne BOBIGNY cedex France 93009
26 Polyclinique Bordeaux Nord Bordeaux CEDEX France 33077
27 Hôpital Duchenne Boulogne-sur-Mer France 62321
28 Hôpital Pierre Oudot Bourgoin-Jallieu France 38300
29 Clinique Pasteur Saint Esprit Brest France 29200
30 CH de Béziers Béziers France 34525
31 CHU Côte de Nacre Caen France 14033
32 CH Cahors France
33 Infirmerie Protestante de Lyon Caluire-et-Cuire France 69300
34 CH William Morey Chalon-sur-Saône France 71100
35 Hôpital Privé Sainte Marie Chalon-sur-Saône France 71100
36 Centre Hospitalier Métropole Savoie Chambery CEDEX France 73011
37 Centre Hospitalier Public du Cotentin Cherbourg France 50102
38 CH Cherbourg France
39 Centre Hospitalier Général Châlons-en-Champagne France 51005
40 CHU Estaing Clermont-Ferrand France 63003
41 Hopitaux Civils de Colmar Colmar France 68024
42 Centre Hospitalier Compiègne CEDEX France 60321
43 CH Contamine sur Arve France
44 Centre Hospitalier Sud Francilien Corbeil-Essonnes France 91106
45 Clinique des Cèdres Cornebarrieu France 31700
46 Clinique des Cèdres Cornebarrieu France
47 Centre Hospitalier de Dax Dax CEDEX France 40107
48 Service de médecine Digne-les-Bains France 04000
49 Hôpital François Mitterand Dijon CEDEX France 21079
50 Institut de Cancérologie de Bourgogne - GRRECC Dijon France 21000
51 Centre Goerges François Leclerc Dijon France 21079
52 CHI Elbeuf-Louviers-Val de Reuil Elbeuf France 76503
53 CH Flers France
54 CHI de Fréjus Saint-Raphaël Fréjus France 83600
55 Centre médical des Forcilles Férolles-Attilly France 77150
56 Centre Hospitalier Gap France 05007
57 Centre Hospitalier Gonesse France 95500
58 CH Gonesse France
59 CHU de Grenoble - Hôpital A. Michallon Grenoble CEDEX France 38043
60 CH Marne La Vallée-Jossigny Jossigny France 77600
61 CHD Vendée La Roche-sur-Yon France 85925
62 Groupe Hospitalier de la Rochelle Ré-Aunis La Rochelle France 17019
63 CH Le Coudray France
64 CH du Mans Le Mans CEDEX 9 France 72037
65 Centre Oscar Lambret Lille France 59037
66 CHRU Hôpital Claude Huriez 4eme EST Lille France 59037
67 Clinique François Chénieux Limoges France 87000
68 CHU Dupuytren Limoges France 87042
69 CH Longjumeau France 91164
70 CHBS - Hôpital du Scorff Lorient CEDEX France 56322
71 Clinique de la Sauvegarde Lyon CEDEX 09 France 69009
72 Clinique Mutualiste Eugène André Lyon France 69003
73 Hôpital Privé Jean Mermoz Lyon France 69008
74 CHU de Lyon - Croix Rousse Lyon France 69317
75 CH ST Joseph-ST Luc Lyon France 69365
76 Hôpital Edouard Herriot Lyon France 69437
77 Centre Radiologie Macon France
78 Hôpital Européen Marseille Marseille CEDEX 03 France 13331
79 Hopital Nord Marseille CEDEX 20 France 13915
80 CHU La Timone Marseille CEDEX 5 France 13385
81 CH de Meaux Meaux France 77100
82 Hôpital Layne Mont-de-Marsan France 40024
83 Hôpital Monod Montivilliers France 76290
84 Centre Hospitalier Montélimar France 26216
85 Centre Hospitalier Morlaix CEDEX France 29672
86 Centre Azuréen de Cancérologie Mougins France 06250
87 Hôpital Privé du Confluent SAS Nantes France 44277
88 Hôpital Américain de Paris Neuilly-sur-Seine France 92200
89 Hôpital Pierre Bérégovoy Nevers CEDEX France 58033
90 Centre Antoine Lacassagne Nice CEDEX 2 France 06189
91 Centre Oncogard Nîmes CEDEX 9 France 30029
92 CHU Carémeau Nîmes France 30029
93 Hôpital de la Source Orléans CEDEX 2 France 45067
94 Hôpital Privé des Peupliers Paris France 75013
95 Hôpital Saint Antoine Paris France 75571
96 HEGP Paris France
97 Hôpital Cochin Paris France
98 Hôpital Saint Louis Paris France
99 Institut Montsouris Paris France
100 Pitié Salpêtière Paris France
101 Centre Hospitalier Pau CEDEX France 64046
102 Hôpital Haut Leveque Pessac CEDEX France 33604
103 CHU Lyon Sud Pierre-Bénite France 64495
104 Centre CARIO - HCPA Plérin France 22190
105 Hôpital de la Milétrie Poitiers France 86021
106 CH Annecy Genevois Pringy France 74374
107 Polyclinique Francheville Périgueux France 24004
108 CHU Robert Debré Reims CEDEX France 51092
109 CHU de Pontchaillou Rennes CEDEX 9 France 35033
110 Centre Eugène Marquis Rennes CEDEX France 35042
111 CH Rodez France
112 Hôpital Drome Nord Romans-sur-Isère France 26100
113 CHU Charles Nicolle Rouen CEDEX 01 France 76031
114 Clinique Mathilde Rouen CEDEX France 76175
115 Hôpital Privé Saint Grégoire Saint Gregoire France 35768
116 ICO - Site René Gauducheau Saint Herblain France 44805
117 Institut de Cancérologie Lucien Neuwirth Saint Priest en Jarez France 42271
118 CH Saint Quentin France
119 Institut Curie Saint-Cloud France 92210
120 Polyclinique Côte Basque Sud Saint-Jean-de-Luz France 64500
121 Centre Hospitalier de Saint-Malo Saint-Malo France 35403
122 Hôpital d'Instruction des Armées Begin Saint-Mandé France 94163
123 Polyclinique Saint Claude Saint-Quentin France 02100
124 CH Saintonge Saintes France 17108
125 CH Morlevat Semur-en-Auxois France 21140
126 CH Senlis CEDEX France 60309
127 Centre Hospitalier Sens CEDEX France 89108
128 CH Région Saint Omer St Omer France 62505
129 Clinique Sainte Anne Strasbourg France 67000
130 Centre Paul Strauss Strasbourg France 67065
131 Hôpitaux du Leman Thonon-les-Bains France 74203
132 Hôpital Sainte Musse Toulon France 83000
133 Hôpital Sainte Musse Toulon France 83000
134 Clinique Saint Jean du Languedoc Toulouse France 31077
135 Hôpitaux Trousseau Tours CEDEX 9 France 37044
136 Centre Hospitalier Valenciennes France 59322
137 CHU de Nancy-Bradois Vandoeuvre les nancy France 54511
138 Institut de Cancérologie de Lorraine Vandoeuvre les nancy France 54519
139 Paul Brousse Villejuif France
140 Centre Hospitalier Villeneuve-Saint-Georges France 94195

Sponsors and Collaborators

  • Federation Francophone de Cancerologie Digestive

Investigators

  • Principal Investigator: Thomas Aparicio, Pr, FFCD member

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Federation Francophone de Cancerologie Digestive
ClinicalTrials.gov Identifier:
NCT02355379
Other Study ID Numbers:
  • PRODIGE34-ADAGE
First Posted:
Feb 4, 2015
Last Update Posted:
Mar 24, 2022
Last Verified:
Mar 1, 2022
Keywords provided by Federation Francophone de Cancerologie Digestive
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 24, 2022